Errayum: BRAFV600E-mutated ovarian serous borderline tumors are at relatively low risk for progression to serous carcinoma (Oncotarget. (2019) 10 (6870–6878) DOI: 10.18632/oncotarget.27326)

M. Herman Chui, Susanne K. Kjaer, Kirsten Frederiksen, Charlotte G. Hannibal, Tian Li Wang, Russell Vang, Ie Ming Shih

Research output: Contribution to journal › Comment/debate › peer-review

Fingerprint

Dive into the research topics of 'Errayum: BRAFV600E-mutated ovarian serous borderline tumors are at relatively low risk for progression to serous carcinoma (Oncotarget. (2019) 10 (6870–6878) DOI: 10.18632/oncotarget.27326)'. Together they form a unique fingerprint.

Medicine & Life Sciences